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This study evaluates life
shortening and the risk of
cancer in mice following 6
weeks of fractionated dose
exposure to clinical proton
beamegenerated neutrons.
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http://dx.doi.org/10.1016/j.ijrobp.2014.01.057Purpose: To evaluate the life span and risk of cancer following whole-body exposure
of mice to neutrons generated by a passively scattered clinical spread-out Bragg peak
(SOBP) proton beam.
Methods and Materials: Three hundred young adult female FVB/N mice, 152 test and
148 control, were entered into the experiment. Mice were placed in an annular cassette
around a cylindrical phantom, which was positioned lateral to the mid-SOBP of a 165-
MeV, clinical proton beam. The average distance from the edge of the mid-SOBP to
the conscious active mice was 21.5 cm. The phantom was irradiated with once-daily
fractions of 25 Gy, 4 days per week, for 6 weeks. The age at death and cause of death
(ie, cancer and type vs noncancer causes) were assessed over the life span of the mice.
Results: Exposure of mice to a dose of 600 Gy of proton beamegenerated neutrons,
reduced the median life span of the mice by 4.2% (Kaplan-Meier cumulative survival,
PZ.053). The relative risk of death from cancer in neutron exposed versus control
mice was 1.40 for cancer of all types (PZ.0006) and 1.22 for solid cancers
(PZ.09). For a typical 60 Gy dose of clinical protons, the observed 22% increased risk
of solid cancer would be expected to decrease by a factor of 10.
Conclusions: Exposure of mice to neutrons generated by a proton dose that exceeds a
typical course of radiation therapy by a factor of 10, resulted in a statistically signif-
icant increase in the background incidence of leukemia and a marginally significant
increase in solid cancer. The results indicate that the risk of out-of-field second solid
cancers from SOBP proton-generated neutrons and typical treatment schedules, is 6 to
10 times less than is suggested by current neutron risk estimates.  2014 Elsevier Inc., Department of Radiation
ton, MA 02114. Tel: (617)
rs.
CA059267 (LE Gerweck).
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Fig. 1. Conscious active mice in Lucite annuli were
exposed to neutrons at a distance of 16.5 to 26.5 cm lateral
to the edge of the mid-spread-out Bragg peak.
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Spread-out Bragg peak (SOBP) proton beams are increas-
ingly being used for the treatment of patients with cancer.
The volume of in-field irradiated normal tissue is signifi-
cantly reduced in proton versus x-ray treated patients;
however, neutrons are generated via the interaction of pro-
tons with the hardware involved in the shaping of beams for
clinical applications, and by proton interactions in the pa-
tient. The use of magnets to appropriately shape and “scan”
or sweep the virgin proton beam through the target volume, a
modality of proton delivery known as active scanning or spot
scanning, substantially reduces the production of neutrons
(1). However, most clinical proton facilities employ beam
scattering or a combination of scattering and active scanning
systems (2), and both methods of beam shaping will likely
be extensively employed in the future.
Neutron-induced second cancer risk in patients treated
with protons has been the subject of substantial discussion
(3, 4). Current neutron risk estimates are primarily derived
from experimental studies, most commonly in rodents (5-18).
Risk estimates vary substantially but generally are in the
range of approximately 10 to 30 times greater than the risk
from the same dose of X or gamma (photon) irradiation
(5-12). However, most neutron risk estimates are based on
the response to relatively low-energy fission neutrons, and
none have evaluated the response to neutrons whose energy
spectrum matches the spectrum produced by typical clinical
SOBP proton beams.
The transferability of risk estimates obtained in animals
to humans is based on the similarity in their response to
photon irradiation. As pertains to humans, animal studies
indicate that the risk of developing cancer is dependent on
dose, sex, age of the test subject at the time of exposure,
and attained age. In addition, when exposed to the same
dose of photon irradiation, the factor increase in solid
cancer (ie, 1.5-1.75 at 1 Gy) is similar across strains of
mice, dogs, and humans (9, 13-17, 19). In addition to
animal-based studies, in vitro studies show that the induc-
tion of mutations, chromosome aberrations, and carcino-
genic transformation is neutron energyedependent (20-22).
Relative to the risk of cancer from exposure to photons, the
International Commission on Radiological Protection
(ICRP) recommended weighting (risk) factor for neutrons,
ranges from a high of 20 for 1-MeV neutrons to 5 for
neutrons greater than 300 MeV (23).
The present study evaluates the risk of cancer in mice
exposed to neutrons generated by a 165-MeV, passively
scattered proton beam over 6 weeks. The relative risk is the
factor increase above the natural background risk of cancer per
unit dose. The excess relative risk is the relative risk minus 1.
Methods and Materials
One hundred fifty-two 10-week old adult female FVB/Nmice
were exposed to SOBP protonegenerated neutrons; 148 miceserved as controls. Irradiated and control mice were placed in
top and sidewall perforated Lucite annuli measuring 20 cm
inner radius, 30 cm outer radius, and 6.25 cm height. Control
mice were transported to and from the treatment facility but
remained outside the treatment area. For irradiation, an
annulus containing 35 to 40 mice was placed around a Lucite
cylindrical phantom (35 cm diameter, 20 cm length), with the
mice positioned lateral to the mid SOBP of a 165 MeV (16.1-
cm range in Lucite), 7 cm diameter, 10 cm modulation width
beam. The average distance from the edge of themid SOBP to
the conscious active mice was 21.5 cm (range 16.5-26.5 cm).
A schematic of the setup is shown in Figure 1. The proton and
resulting neutron dose to the mice was chosen with the intent
of avoiding extremes, that is, no change in the background
cancer incidence or all mice dying of cancer. Were no change
in the background incidence of cancer to occur, an estimate of
the upper limit of risk per treatment course could be estimated,
but the numerical value of the risk could not be defined.
Similarly, if all exposedmice died of cancer, the increased risk
would be equal to or greater than that resulting from the
administered dose but also undefined.
Three principle factors were considered when choosing
the proton dose to the phantom: (1) the neutron dose to the
mice per proton dose to the phantom; (2) the relative risk of
cancer per gray in mice exposed to photons as well as the
carcinogenicity of fission neutrons versus photons; and (3)
the energy spectrum differences between neutrons gener-
ated by clinical proton beams versus fission neutrons.
Monte Carlo calculations utilizing the TOPAS platform
were used to estimate the neutron dose to the mice per proton
dose to the phantom (24). The calculated dose to the mice
randomly positioned in the annulus was 3.6  104 Gy
neutrons per Gy protons to the phantom. The neutron dose
was also measured with PB-PND neutron dosimeters (Bub-
ble Technology Industries, Chalk River, Canada). At a po-
sition midway between the inner and outer wall of the
annulus, the dosimeters yielded a dose equivalence of 2.3 
103 Sv neutrons perGy protons to the phantom.Aswas used
Fig. 2. Lifetime cumulative (cum.) survival of control
and neutron exposed mice. Intentionally sacrificed non-
Volume 89  Number 1  2014 Second cancer risk in proton therapy 163by the chamber manufacturer to convert Gy to Sv, National
Council on Radiation Protection and Measurements, Report
38 (NCRP 38) and the fluence-weighted neutron energy
spectrum of the 165-MeV beam was used to convert Sv
neutrons toGy neutrons. This conversion resulted in a dose of
3.2  104 Gy neutrons per Gy protons (ie, the agreement
between the Monte Carlo simulations and measurements is
well within the expected uncertainties). Additional details
pertaining to neutron dose and equivalent dose are provided
in the supplementalmaterial: Supplemental neutron dose and
dose equivalent at www.redjournal.org.
As previously noted, the lifetime relative risk of solid
cancer following acute doses of photons (ie, approximately
1.5-1.75 Gy1), does not significantly vary across 5 mouse
strains, even though the background incidence of total cancers
and particular cancer types is strain-dependent (9, 13-17, 19).
The energy-weighted fluence spectrum of neutrons
generated by typical clinical proton beams including the
165-MeV beam used in this study, substantially exceeds the
energy-weighted fluence of fission neutrons employed for
previous experimental cancer risk estimates (25). The
higher energy neutrons give rise to substantially higher
energy protons upon interacting in the exposed subject than
pertains to protons arising from fission neutrons (26).
Because the LET of protons is inversely related to proton
energy, we speculated that the lower LET protons more
closely approximate the carcinogenicity of photons than
pertains to protons generated by fission neutrons. Thus, for
planning purposes, it was hypothesized that the relative
carcinogenic risk of 165-MeV protonegenerated neutrons
administered over 6 weeks might be substantially lower
than pertains to current fission neutron based risk estimates,
and thus in the range of 5 versus photons. Based on a
relative risk factor of solid cancer of 1.6, from exposure to
1 Gy of photons, and a speculated neutron relative bio-
logical effect of 5, administration of 600 Gy protons to the
phantom resulting in 216 mGy neutrons to the mice would
increase the lifetime background incidence of cancer from
approximately 50% (27) to 80%, or by a factor of 1.6.
Following their entry into the experiment and with
infrequent exceptions, all mice were examined once daily
until natural death or sacrifice: 13.7% were sacrificed when
moribund and not expected to live for an additional 24
hours; 3.7% were sacrificed due to the development of ul-
cerative dermatitis, subcutaneous lipomas exceeding 14
mm in diameter, and 1 (0.3%) with a subcutaneous fibroma.
More than 97% of all dying or sacrificed mice were
autopsied, at which time an initial assessment of the cause
of death was made. Tissue was collected for histopatho-
logic evaluation to further confirm or establish the cause of
death, cancer and type, or not cancer.moribund and abruptly dying mice were censored. NZ139
control and 138 neutron exposed mice. Bars are 95%
confidence intervals for the control cohort of animals at the
10%, 50% and 90% cumulative survival level and for the
exposed mice at the same age as the control mice. Log-rank
test PZ.053.Results
The mean life span, regardless of the cause of death, was
794 days in the control and 756 days in the neutron-exposed mice (PZ.03 Kaplan-Meier, log-rank). In addition
to the intentionally sacrificed nonmoribund mice (PZ.3 for
control vs neutron-exposed mice), 10 exposed and 2 control
mice abruptly died during the last 2 weeks of neutron
exposure and up to 30 days thereafter (90-144 days of age).
The mice were active and of normal body weight before
and at the time of death. Autopsy and histologic exami-
nation of tissues collected from the mice were unrevealing,
and the cause of death was not resolved. Similar rates of
abrupt death without resolved cause, and in the absence of
imposed hazards, have previously been noted in FVB/N
mice (28). After the censoring of intentionally sacrificed
and early abruptly dying mice, the P value for difference in
cumulative survival was .053 (Kaplan-Meier, log-rank;
Fig. 2). Neutron exposure reduced the median life span of
control mice by 4.8% regardless of the cause of death (no
censoring) and 4.2% after censoring. Uroschesis was the
leading cause of noncancer deaths in control and exposed
mice.Cancer deaths
For the calculation of cancer deaths, mice for which the
cause of death (cancer vs noncancer) could not be deter-
mined due to cannibalism or deterioration of tissue (4
control and 5 neutron exposed) were censored. Following
all censoring, 135 control and 133 neutron-exposed mice
remained at risk.
The cumulative fraction of mice dying from cancer is
shown in Figure 3A. During the first 400 days after
Fig. 3. Cumulative deaths as a fraction of all deaths over the lifetime of the mice. (A) Death from cancer of all types
(PZ.0006). (B) Deaths due to lymphocytic leukemia (PZ.004). (C) Death from solid cancer (PZ.09). Cum.Z cumulative.
Gerweck et al. International Journal of Radiation Oncology  Biology  Physics164irradiation, relatively few and a comparable number of
cancer deaths were observed in the control and neutron-
exposed mice. Beginning at approximately 500 days of
age, the number of cancer deaths in exposed mice began to
exceed the number of deaths in control mice. Over their life
span, 69 control mice died of cancer and 66 from noncancer
causes; for the neutron-exposed mice, 95 died from cancer
and 38 from noncancer causes. Neutron exposure increased
the number of cancer deaths by 40% (PZ.0006, c2).
Three cancer types, lymphocytic leukemia (LL), alveolar
bronchiolar carcinoma and histiocytic sarcoma, accounted
for approximately 75% of all cancer deaths in both control
and neutron-exposed mice. Of these, LL was the most
radiogenic cancer with a lethal incidence of 4% in control
mice (5 deaths) and 14% (18 deaths) in neutron-exposed
mice, PZ.004 (Fig. 3B). Other hematopoietic cancer sub-
types were not found in control or exposed FVB/Nmice. The
increased number and shortened median age at death from
LL in exposed mice, 667.5 days versus 804 days in control
mice, substantially contributed to life shortening. Alveolar
bronchiolar carcinoma was the most common tumor in
control (30 of 135) and neutron-exposed mice (41 of 133),
PZ.10. Thirty-three cancer deaths (17 control and 16
neutron exposed) were attributed to histiocytic sarcoma, a
nonradiogenic and rare cancer in humans. In 4 mice (2 con-
trol and 2 exposed), tumors of 2 histological typeswere found
at the time of death. This included 9 histologically benign
tumors in the control and 9 in the neutron-exposed mice. The
majority of the benign but lethal tumors in both groups were
teratomas. Although histologically benign, these tumors
grew to a huge mass in the abdominal cavity with severe
organ compression, leading to early death in the host mice, as
seen in Supplemental Figure 7B and 7C. A listing of all tu-
mors leading to the death of the mice is provided in
Supplemental Table 1; histopathologic slides are provided in
Supplemental Figures 1 through 8 with associated legends.
Additional histopathologic details are provided in the sup-
plemental histopathology findings at www.redjournal.org.
Cumulative deaths from solid cancer are shown in
Figure 3C. For control mice, 64 of 135 mice at risk or 0.47(95% confidence interval 0.39-0.56), and 77 of 133
neutron-exposed mice or 0.58 (95% confidence interval
0.50-0.66) died of solid cancer. The relative risk of 1.22
was of marginal statistical significance (PZ.09). Reclas-
sification of all histologically benign but lethal tumors from
the “cancer” cause of death category to the “other” cause of
death category, leads to a minor change in the relative risk
factor from 1.22 to 1.25, without a decrease in the P value.Discussion
The principle finding of this study is that a dose of 216
mGy of clinical proton beamegenerated neutrons over 6
weeks gives rise to a 1.4-fold increase in the lifetime
incidence of solid cancer plus lymphocytic leukemia, a 3.6-
fold increase in lymphocytic leukemia, and a marginally
significant 1.22-fold increase in the incidence of solid
cancer, the latter of which constitutes >90% of all cancers
in humans. As previously noted, the relative risk of solid
cancer from 1 Gy acute photons in rodents, dogs, and
humans is similar: 1.5 to 1.75. Given a risk factor of 1.6 for
photons at 1 Gy, the carcinogenicity of 216 mGy neutrons
is equivalent to 0.36 Gy photons, that is, 1.7 times more
carcinogenic than photons. The 1.7 greater risk from neu-
trons generated by the 165-MeV clinical proton beam is
thus 6 to 10 times less than pertains to the 10- to 30-fold
greater risk observed in previous studies using fission en-
ergy neutrons (5-12). It similarly contrasts with the 9.9
calculated risk factor of neutrons produced by 165-MeV
proton beam in this study versus photons, based on ICRP
report 92 (23). Had either the experimentally measured
fission neutron risk factors or ICRP 92erecommended risk
factors pertained to the present study, all or nearly all of the
neutron-exposed mice in this study likely would have died
of solid cancer or leukemia.
As seen in the present study, the radiogenicity of lym-
phocytic leukemia substantially exceeds the radiogenicity
of solid cancer, as also pertains to acute lymphocytic leu-
kemia and myeloid leukemia subtypes in the human
Volume 89  Number 1  2014 Second cancer risk in proton therapy 165population (19, 29). A recent comprehensive report notes
that a precise estimate of the risk factor for acute lym-
phocytic leukemia in the survivors of Hiroshima and
Nagasaki is not possible because of the absence of inci-
dence and mortality data from 1945 to 1950 (30). The
absence of this data, as well as a somewhat different
equivalent age of peak incidence of acute lymphocytic
leukemia in humans and lymphocytic leukemia in mice,
suggests caution in using the results of the present study for
the prediction of acute lymphocytic leukemia risk in the
human population.
Because a dose of 600 Gy to the phantom and resulting
neutron dose to the mice is substantially greater than per-
tains to a patient receiving proton treatment, the question
arises of how risk from 216 mGy neutrons extrapolates to
risk at lower doses. In exhaustive studies, Storer and Fry
(31) and Heidenreich et al (9) examined the relationship
between dose and cancer risk in male and female mice
exposed to single and fractionated doses of fission neutrons.
These studies showed that a linear no-threshold dose-
response relationship pertained for fractionated doses as
low as 2.5 mGy per fraction. Thus, because 600 Gy protons
give rise to a 22% increased cancer incidence, 60 Gy pro-
tons may be expected to give rise to a 2.2% increase in
lifetime out-of-field solid cancer risk.
The results of this study indicate that the risk of cancer
from clinical SOBP-generated neutrons is 1.7 times greater
than pertains to an equivalent acute dose of gamma rays.
This conclusion is based on the assumption that the FVB/N
mouse is not uniquely sensitive or resistant to radiation-
induced cancer. Interestingly, in one of the few studies to
evaluate cancer risk from higher energy (ie, d(50)-Be
neutrons), the relative biological effectiveness for cancer
induction relative to photons was estimated to lie “probably
between 2 and 3,” that is, substantially lower than studies
using fission neutrons and similar to the results found in the
present study (11). Additional studies with lower-energy
proton beamegenerated neutrons are needed to further
investigate and validate the relationship between neutron
energy and neutron carcinogenicity.
Data pertaining to the risk of out-of-field second cancer
in proton-treated patients is limited (32-34). In a retro-
spective study, Chung et al examined cancer incidence in
patients receiving mixed proton/photon (protons being the
predominant dose component) versus photons (32).
Although longer follow-up is needed (32, 33), second-
cancer incidence (combined in-field and out-of-field) did
not significantly differ between the photon- versus proton-
treated cohort over the approximately 6-year median
follow-up period. In a recently published 2014 study (34),
Sethi et al examined in-field and out-of-field cancer inci-
dence in proton versus photon-treated patients with reti-
noblastoma. In-field cancer was significantly higher in
photon-treated patients. With an approximately 7-year
median follow-up, the incidence of out-of-field cancer did
not significantly differ in the proton- versus photon-treated
patients.The present study pertains to the lifetime risk of cancer
in young-adult mice, which were 10 to 16 weeks of age at
the time of exposure. As pertains to humans, relative to the
risk from exposure during young adulthood, cancer risk
increases with decreasing age at exposure and more
moderately decreases with increasing age at exposure (16).
Given their significantly higher relative risk per Gy and
shorter latency, leukemia and solid-tumor risk are sepa-
rately reported. Risk estimates obtained in this study
pertain to female mice and are compared with the risk in
females in the human population. Radiation-induced solid
cancer risk is approximately 50% lower in males than fe-
males in humans and appears to be similarly lower in male
mice (9, 19).Conclusion
Exposure of mice to neutrons generated by 600 Gy of a
165-MeV SOBP proton beam at 21.5 cm lateral to the edge
of the mid SOBP results in a 40% increase in deaths from
solid cancer plus lymphocytic leukemia. For solid cancer,
the observed 22% increased risk is of marginal statistical
significance. The results indicate that the lifetime risk of
out-of-field cancer from neutrons generated by a passively
scattered SOBP beam, administered over 6 weeks, is 6 to
10 times lower than current risk estimates.References
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